Cheng Pan, He Jichen, Cheng Pingping, Chen Kaixia, Zhao Guangyu
Department of Pharmacy, Jingjiang People's Hospital Affiliated to Yangzhou University, Taizhou, China.
School of Public Health, Guangxi Medical University, Nanning, China.
Front Oncol. 2024 Dec 2;14:1468569. doi: 10.3389/fonc.2024.1468569. eCollection 2024.
Adebrelimab is a humanized monoclonal antibody against programmed death-ligand 1 (PD-L1) and is also a novel immune checkpoint inhibitor, which has been used in the first-line treatment of extensive stage small cell lung cancer (SCLC) with its unique mechanism of action and good clinical efficacy. Significant progress has been made in the treatment of adebrelimab in other malignancies such as non-small cell lung cancer, triple-negative breast cancer, esophageal squamous cell carcinoma, and the treatment of SCLC at different stages is also being explored. Therefore, adebrelimab emerges as a promising new treatment option for patients with small cell lung cancer (SCLC) and other types of malignant tumors.
阿得贝利单抗是一种抗程序性死亡配体1（PD-L1）的人源化单克隆抗体，也是一种新型免疫检查点抑制剂，凭借其独特的作用机制和良好的临床疗效，已被用于广泛期小细胞肺癌（SCLC）的一线治疗。阿得贝利单抗在其他恶性肿瘤如非小细胞肺癌、三阴性乳腺癌、食管鳞状细胞癌的治疗方面取得了显著进展，不同阶段SCLC的治疗也在探索中。因此，阿得贝利单抗成为小细胞肺癌（SCLC）及其他类型恶性肿瘤患者一种有前景的新治疗选择。
